PDZK1 Regulates the Stability and Function of ADRB2 to Prevent Vascular Remodelling in Hypertension
Clinical and Experimental Pharmacology and Physiology · 2025
DOI: 10.1111/1440-1681.70085 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, 2025. Verfasst von Haoran Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, China. Hauptthemen laut MEDLINE: Receptors, Adrenergic, beta-2, Hypertension, Vascular Remodeling, Carrier Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Young Medical Talents Funding Project of the First Affiliated Hospital of Harbin Medical University, Postdoctoral Scientific Research Developmental Fund of Heilongjiang Province.
Abstract (Originalsprache)
In this study, we found that PDZK1, a scaffold protein, interacts with the β₂‐adrenergic receptor (ADRB2) through its PDZ domains, stabilising ADRB2 by inhibiting its ubiquitination and proteasomal degradation. This study explored the PDZK1–ADRB2 interaction and its role in hypertension‐induced vascular remodelling. Using PDZK1 knockout mice infused with angiotensin II, we found that PDZK1 deficiency further exacerbates angiotensin II‐induced hypertension, vascular dysfunction, and vascular remodelling. Mechanistically, PDZK1 stabilises ADRB2 protein by preventing its ubiquitination and proteasomal degradation, thereby maintaining ADRB2‐mediated vasodilation. Additionally, PDZK1 prevents ADRB2 internalisation and its interaction with β‐arrestin, thereby inhibiting β‐arrestin–mediated ERK activation and suppressing vascular smooth muscle cell (VSMC) phenotypic switching. This mechanism contributes to vascular protection under hypertensive conditions. Targeting the PDZK1/ADRB2 interaction may provide a novel therapeutic strategy for hypertension‐related vascular complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
- Heilongjiang Province Key Laboratory of Cardiovascular Disease Sound Light Electromagnetic Diagnosis and Treatment, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
- The First College for Clinical Medicine, Harbin Medical University, Harbin, China.
Förderung
- Young Medical Talents Funding Project of the First Affiliated Hospital of Harbin Medical University
- Postdoctoral Scientific Research Developmental Fund of Heilongjiang Province
Zitieren
APA
Zhang, H., Meng, Y., Li, D., Zheng, W., Bu, W., Shi, Z., Liu, C., Zhao, M., Wang, H., Bai, Y., Luo, L., Zhao, D., & Chi, J. (2025). PDZK1 Regulates the Stability and Function of ADRB2 to Prevent Vascular Remodelling in Hypertension. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/1440-1681.70085
Vancouver
Zhang H, Meng Y, Li D, Zheng W, Bu W, Shi Z, et al. PDZK1 Regulates the Stability and Function of ADRB2 to Prevent Vascular Remodelling in Hypertension. Clinical and Experimental Pharmacology and Physiology. 2025. doi:10.1111/1440-1681.70085
BibTeX
@article{Zhang2025,
author = {Zhang, Haoran and Meng, Yan and Li, Dandan and Zheng, Wenjing and Bu, Wenjie and Shi, Zhiyu and Liu, Chunnan and Zhao, Meng and Wang, Huiying and Bai, Yufeng and Luo, Liying and Zhao, Dechao and Chi, Jinyu},
title = {PDZK1 Regulates the Stability and Function of ADRB2 to Prevent Vascular Remodelling in Hypertension},
journal = {Clinical and Experimental Pharmacology and Physiology},
year = {2025},
doi = {10.1111/1440-1681.70085}
}
EUVIMED